Showing results (51-60 of 78) with videos related to
Sort By:
Pageof 8
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Acute myeloid leukemia, version 2.2013Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.Cancer Research Communications|June 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 YearsEric D Eisenmann, Ronan Swords, Ying Huang, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 7, 2021
Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutationsLaura F Newell, Jennifer Dunlap, Ken Gatter, et al.Blood Advances|July 17, 2023
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratoriesUma Borate, Fei Yang, Richard Press, et al.Hematological Oncology|May 7, 2024
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemiaSudhir Manda, Bertrand M Anz, Christopher Benton, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 21, 2015
Acute Lymphoblastic Leukemia, Version 2.2015Joseph C Alvarnas, Patrick A Brown, Patricia Aoun, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i>-Mutated or <i>KMT2A</i>-Rearranged AMLJoshua F Zeidner, Tara L Lin, Rina Li Welkie, et al.Blood Advances|February 11, 2026
Conventional Therapy vs HMA or LDAC ± Venetoclax in Older Adults With AML: Systematic Review and Meta-analysisSara Ibrahim, Barbara Burgos-Mansilla, Yetiani Roldan, et al.Pageof 8